A pair of trials show taking Pozen's Trexima is more effective in treating migraine headaches than GlaxoSmithKline's Imitrex, the current leading drug for the problem. Trexima, which would be produced by GSK if the FDA approves a pending application, combines Imitrex and naproxen and provided pain relief after two hours in 57% to 65% of patients in trials, compared to 50% to 55% of patients taking Imitrex.

Full Story:

Related Summaries